NCT06976736

A Long Term Follow-up Study of TScan TCR-T Products

A Long-term Follow-up Study to Assess Safety in Participants Who Received an Investigational T-Cell Receptor Engineered T-Cell (TCR-T) Product

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 1,000 (estimated)
• Sponsor: TScan Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 110 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this Long-Term Follow-Up (LTFU) study is to monitor participants who have previously received TSC-100 or TSC-101 TCR-T therapies in the TSCAN-001 study. Participants will be monitored for 15 years from the date of TCR-T cell therapy administration to assess long-term safety and efficacy.

Detailed description

Participants will enroll in this LTFU study after completing the TSCAN-001 interventional trial. No additional study drug will be administered; however, participants may receive other cancer treatments as needed while being monitored for long-term safety. Enrollment will occur after completion of the TSCAN-001 study, and participants will be monitored for safety and efficacy over a 15 year period.

Conditions

• AML
• ALL
• MDS

Interventions

Type	Name	Description
OTHER	Observational	Long Term Follow-Up for participants treated with TSC-100 or TSC-101 TCR-T products

Timeline

• Start date: 2025-09-09
• Primary completion: 2040-09-01
• Completion: 2040-09-01
• First posted: 2025-05-16
• Last updated: 2025-09-10

Locations

2 sites across 1 country: United States